Psilocybin prevents chemotherapy-induced peripheral neuropathy through mitochondrial trafficking preservation

Paper. Heles M, Pasvolsky L, Sathishkumar H et al.. Science, 3 Sep 2026.

Tags: Psilocybin, Pain, Cancer.

Weekly Science Digest, 20 Jul 2026 to 2 Oct 2026, finding 1: Psilocybin prevented chemotherapy nerve damage in mice

Two doses of psilocybin before platinum or taxane chemotherapy stopped peripheral neuropathy from developing, across repeated chemo cycles, without weakening the chemotherapy against tumors. The authors trace the effect to nerve cells keeping their mitochondria moving along the axon.

How much weight it carries: Animal study. A human trial testing psilocybin to prevent chemo-induced neuropathy is registered at MD Anderson. (Mice, Preclinical, Peer reviewed)

Weekly Science Digest, 29 Aug 2026 to 4 Sep 2026, finding 1: Psychedelics turn up in oncology

Psilocybin prevented chemotherapy nerve damage in mice without blunting the chemo.

Two doses before platinum- or taxane-based chemotherapy preserved tactile sensitivity and nerve fibre endings by keeping mitochondria moving along axons, and an accompanying Science commentary frames this as prophylaxis rather than treatment. A separate Cancer Discovery paper reports a non-hallucinogenic LSD analogue boosting the immune response to colorectal cancer; both results are preclinical.

Read the original

—
Node—
Statuslive
Throughput—